# Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101

> **NCT03644459** · PHASE1 · WITHDRAWN · sponsor: **Lynkcell Inc.**

## Conditions studied

- Ovarian Cancer
- Cervical Cancer
- Colorectal Cancer
- Stomach Cancer

## Interventions

- **BIOLOGICAL:** LYN00101

## Key facts

- **NCT ID:** NCT03644459
- **Lead sponsor:** Lynkcell Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-04-03
- **Primary completion:** 2020-06
- **Final completion:** 2020-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Unable to recruit individuals for the study
- **Last updated:** 2020-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03644459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03644459, "Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03644459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*